27 July 2021

Download as PDF

Results from a phase III trial supported by AVARA Pharmaceuticals Services has revealed comparisons between the efficacy and safety of Bevacizumab Biosimilar FKB238 versus originator Bevacizumab. 

The drug FKB238 has shown efficacy and safety profiles within the parameters set by EU and US regulatory authorities for being considered a biosimilar to reference Bevacizumab. This is an important discovery as biosimilar drugs present an important avenue to achieve treatment affordability while retaining the efficacy demonstrated by the reference biological agent. 

The conclusions of the phase III trial confirmed that efficacy equivalence was demonstrated between the two drugs, and their safety profiles were similar. There were no meaningful differences in efficacy and safety between FKB238 and Bevacizumab in patients with non-squamous non-small-cell lung cancer (non-sq-NSCLC). 

This presents an important step towards bringing valuable treatments for cancer to a broader population of patients.

tranScrip is delighted to have been a part of the clinical development of Bevacizumab Biosimilar FKB238 and other anti-cancer medicines.

Contact us to learn how we can help you achieve your development objectives across a multitude of therapy areas. 

Reference:
Springer